Global framework for biosimilars "is now crucial"

Article Date: 25/04/2012 06:00
Global framework for biosimilars "is now crucial"

Vacancy Search

Quick job search

Advanced Search

Latest News

Event – BioLineRx and Bellerophon hope for a matrix revolution

The cardiac matrix under development by BioLineRx and Bellerophon Therapeutics to limit tissue damage after heart attack has already been shown to be safe and well tolerated. Results due by...

Sanofi’s Jevtana given last-minute CDF reprieve

Sanofi’s Jevtana given last-minute CDF reprieve

NHS Trusts’ funding gap rises to nearly £1bn

NHS Trusts’ funding gap rises to nearly £1bn

All eyes on brodalumab fallout

After Amgen’s shock decision on Friday to dump the AstraZeneca-partnered psoriasis antibody brodalumab, citing risk of suicide, attention should turn to competing agents from Novartis and...

Bayer's Stivarga wins appeal to stay on CDF

Bayer's Stivarga wins appeal to stay on CDF

BMA slams seven-day GP services 'obsession'

BMA slams seven-day GP services 'obsession'

Upcoming events: a dosing decision for BioMarin, plus Roche to get Alzheimer’s data

Welcome to your weekly digest of approaching regulatory and clinical readouts. Data from BioMarin’s phase II trial of the achondroplasia project BMN 111, expected this month or next, will...

Surprise resurrection sees Aveo and Prima pining for the fjords

When it comes to dead parrots making comebacks it could not have got much more extreme than the severely depressed Aveo Oncology and Prima Biomed, whose apparently deceased oncology projects...

Novartis' Afinitor extends progression-free survival in NET

Novartis' Afinitor extends progression-free survival in NET

Regeneron/Sanofi drug improves RA symptoms in PhIII trial

Regeneron/Sanofi drug improves RA symptoms in PhIII trial
more news